Roche (RHHBY) Slammed With Partial Holds for Two Combo Cancer Trials
Kaleido Biosciences Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist (MRK) Exec
Harvard Biotech Guru, VCs Launch LifeMine Therapeutics With $55 Million Series A
Bay Area's Ultragenyx (RARE) Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics (DMTX)
Nabriva (NBRV)'s Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials
Bill & Melinda Gates Foundation Sinks $40 Million Into Immunocore for Infectious Disease R&D
Amgen (AMGN), Allergan (AGN) Make History With First Cancer Biosimilar OK—Will Take on Genentech (RHHBY)'s $6 Billion Best-Seller
Show Me The Money: Bay Area’s Top 5 Venture Capital-Backed Biotechs
Massachusetts' Flexion (FLXN) Terminates R&D Deal With AstraZeneca PLC (AZN)
San Diego's Halozyme (HALO) Lands Monster R&D Deals Worth $2 Billion+ From Bristol-Myers Squibb (BMY) and Roche (RHHBY)
Down But Not Out: Juno (JUNO) Preps For Second Round Of CAR-T Cancer War
3 California Biotechs That Have Already Gained 300% or More This Year
Teva (TEVA) Gains Another $2.48 Billion For Selling The Last Of Its Women’s Health Portfolio
Sans Biogen (BIIB)'s $485 Million Buyout Option, Rodin Nabs $27 Million For Alzheimer's
As Alexion (ALXN) Moves To Boston, Yale Eyes HQ Space For New Biotech Startups
Vivek Ramaswamy's Urovant Sciences Taps Former AVANIR (AVNR) Exec As Its New CEO
Which Of These 5 Will Be The Best-Selling Drug Worldwide In 2020?
Love Handles Get Dissolved By New Skin Patch, University of North Carolina Study Reveals
See All News >